Syndax and Nektar kick off melanoma collaboration

31 May 2018

Syndax Pharmaceuticals (Nasdaq: SNDX) and Nektar Therapeutics (Nasdaq: NKTR) have agreed a non-exclusive clinical collaboration to test NKTR-214 in combination with Syndax’s entinostat.

The firms will launch a clinical trial to test the safety and efficacy of the combination against metastatic melanoma in patients who have progressed after treatment with a checkpoint inhibitor.

The trial will evaluate progression-free survival and overall survival, and correlative biomarker analyses will be used to identify patients with enhanced responses to the combination.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK